Synthesis

Picoline borane (PICB) was developed with the objective of enhancing the thermal stability of pyridine borane (PYB). The incorporation of the ortho methyl group not only imparts the desired stability to the reagents but also gives distinctive reactivity, particularly evident in the context of reductive amination. PICB demonstrates utility under neat conditions with liquid substrates; […]

Sodium cyanoboronhydride (NaBH3(CN)) as a reducing agent for reductive amination has lower solubility in aprotic solvents, restricting its application when these solvents are required. To overcome this limitation, Hutchins introduced tetrabutylammonium cyanoborohydride (TBAC), a soluble compound not only in protic and polar solvents, but also in most aprotic solvents such as DCM, hexane, benzene, and

Reductive amination, also termed reductive alkylation, is one of the most popular methods for forming C-N bonds. The pivotal Borch reaction, disclosed in 1971, laid the groundwork for borohydride-promoted reductive amination. This reaction leverage sodium cyanoborohydride (NaBH3(CN)) as a reducing reagent to condense a ketone/aldehyde with an amine/aniline, forming a C-N bond. The reduction potential

Sodium triacetoxyborohydride (NaBH(OAc)3, STAB-H) serves as a popular reducing reagent for direct reductive amination (DRA), alongside sodium cyanoboronhydride (NaBH3(CN)). In comparison to NaBH3(CN), STAB-H offers several advantages. Firstly, STAB-H is a safer reagent because it does not release toxic cyanide ions. Secondly, STAB-H exhibits high reactivity in various aprotic solvents, including DCE, THF, and dioxane.

Vestipitant (GW597599), a potent NK-1 antagonist, consists of an asymmetric urea moiety. The synthesis of this urea functional group presents challenges due to the complex nature of the reaction partners, coupling reagents, stoichiometry of reactants/reagents, temperature, and so on. Throughout the process development, a diverse array of byproducts was observed, necessitating careful optimization. To mitigate

A significant number of interventional and observational clinical trial records, totaling more than 790, are associated with either KRAS itself or the pathway in which KRAS is involved. These meticulously designed interventional studies serve the purpose of evaluating potential treatments for cancers, including vaccines, monoclonal antibodies, and small molecules. Notably, there exist more than 22

TNO155, a clinical-stage SHP2 inhibitor, was synthesized using a divergent approach employing building blocks 11 and 12 with the longest linear sequence of 9 steps. The chiral methyl group in the spiro-ring of 11 was obtained from a chiral pool starting material, L-Lactide 3, while the chiral amine was generated through diastereoselective hydrogenation of oxime